TY - JOUR
T1 - A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
AU - Ma, Cynthia X.
AU - Ellis, Matthew J.C.
AU - Petroni, Gina R.
AU - Guo, Zhanfang
AU - Cai, Shi Rong
AU - Ryan, Christine E.
AU - Craig Lockhart, A.
AU - Naughton, Michael J.
AU - Pluard, Timothy J.
AU - Brenin, Christiana M.
AU - Picus, Joel
AU - Creekmore, Allison N.
AU - Mwandoro, Tibu
AU - Yarde, Erin R.
AU - Reed, Jerry
AU - Ebbert, Mark
AU - Bernard, Philip S.
AU - Watson, Mark
AU - Doyle, Laurence A.
AU - Dancey, Janet
AU - Piwnica-Worms, Helen
AU - Fracasso, Paula M.
N1 - Funding Information:
Department of Pathology at Washington University School of Medicine for tumor TP53 sequencing. We would like to thank Dr. Katherine Deschryver for reviewing the pathology slides. We would like to thank members of the SPECS team, Sherri Davies, Elaine Mardis, Jacqueline Snider, and Tammi Vickery, for assistance with the PAM50 Breast Cancer Intrinsic ClassiferTM molecular subtype analysis. Grant Support: NIH R21 CA128369 (P. M. F.), Susan G. Komen Foundation KG08155 (C.X.M. and H.P.-W.), and NIH U01 CA114722 (M.J.E).
PY - 2013/1
Y1 - 2013/1
N2 - Mutations in TP53 lead to a defective G1 checkpoint and the dependence on checkpoint kinase 1 (Chk1) for G2 or S phase arrest in response to DNA damage. In preclinical studies, Chk1 inhibition resulted in enhanced cytotoxicity of several chemotherapeutic agents. The high frequency of TP53 mutations in triple negative breast cancer (TNBC: negative for estrogen receptor, progesterone receptor, and HER2) make Chk1 an attractive therapeutic target. UCN-01, a non-selective Chk1 inhibitor, combined with irinotecan demonstrated activity in advanced TNBC in our Phase I study. The goal of this trial was to further evaluate this treatment in women with TNBC. Patients with metastatic TNBC previously treated with anthracyclines and taxanes received irinotecan (100-125 mg/m2 IV days 1, 8, 15, 22) and UCN-01 (70 mg/m2 IV day 2, 35 mg/m2 day 23 and subsequent doses) every 42-day cycle. Peripheral blood mononuclear cells (PBMC) and tumor specimens were collected. Twenty five patients were enrolled. The overall response (complete response (CR) + partial response (PR)) rate was 4 %. The clinical benefit rate (CR + PR + stable disease ≥6 months) was 12 %. Since UCN-01 inhibits PDK1, phosphorylated ribosomal protein S6 (pS6) in PBMC was assessed. Although reduced 24 h post UCN-01, pS6 levels rose to baseline by day 8, indicating loss of UCN-01 bioavailability. Immunostains of γH2AX and pChk1S296 on serial tumor biopsies from four patients demonstrated an induction of DNA damage and Chk1 activation following irinotecan. However, Chk1 inhibition by UCN-01 was not observed in all tumors. Most tumors were basal-like (69 %), and carried mutations in TP53 (53 %). Median overall survival in patients with TP53 mutant tumors was poor compared to wild type (5.5 vs. 20.3 months, p = 0.004). This regimen had limited activity in TNBC. Inconsistent Chk1 inhibition was likely due to the pharmacokinetics of UCN-01. TP53 mutations were associated with a poor prognosis in metastatic TNBC.
AB - Mutations in TP53 lead to a defective G1 checkpoint and the dependence on checkpoint kinase 1 (Chk1) for G2 or S phase arrest in response to DNA damage. In preclinical studies, Chk1 inhibition resulted in enhanced cytotoxicity of several chemotherapeutic agents. The high frequency of TP53 mutations in triple negative breast cancer (TNBC: negative for estrogen receptor, progesterone receptor, and HER2) make Chk1 an attractive therapeutic target. UCN-01, a non-selective Chk1 inhibitor, combined with irinotecan demonstrated activity in advanced TNBC in our Phase I study. The goal of this trial was to further evaluate this treatment in women with TNBC. Patients with metastatic TNBC previously treated with anthracyclines and taxanes received irinotecan (100-125 mg/m2 IV days 1, 8, 15, 22) and UCN-01 (70 mg/m2 IV day 2, 35 mg/m2 day 23 and subsequent doses) every 42-day cycle. Peripheral blood mononuclear cells (PBMC) and tumor specimens were collected. Twenty five patients were enrolled. The overall response (complete response (CR) + partial response (PR)) rate was 4 %. The clinical benefit rate (CR + PR + stable disease ≥6 months) was 12 %. Since UCN-01 inhibits PDK1, phosphorylated ribosomal protein S6 (pS6) in PBMC was assessed. Although reduced 24 h post UCN-01, pS6 levels rose to baseline by day 8, indicating loss of UCN-01 bioavailability. Immunostains of γH2AX and pChk1S296 on serial tumor biopsies from four patients demonstrated an induction of DNA damage and Chk1 activation following irinotecan. However, Chk1 inhibition by UCN-01 was not observed in all tumors. Most tumors were basal-like (69 %), and carried mutations in TP53 (53 %). Median overall survival in patients with TP53 mutant tumors was poor compared to wild type (5.5 vs. 20.3 months, p = 0.004). This regimen had limited activity in TNBC. Inconsistent Chk1 inhibition was likely due to the pharmacokinetics of UCN-01. TP53 mutations were associated with a poor prognosis in metastatic TNBC.
KW - Chk1
KW - Irinotecan
KW - Metastatic triple negative breast cancer
KW - TP53
KW - UCN-01
KW - p53
UR - http://www.scopus.com/inward/record.url?scp=84877947967&partnerID=8YFLogxK
U2 - 10.1007/s10549-012-2378-9
DO - 10.1007/s10549-012-2378-9
M3 - Article
C2 - 23242585
AN - SCOPUS:84877947967
SN - 0167-6806
VL - 137
SP - 483
EP - 492
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 2
ER -